本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002099 证券简称：海翔药业 公告编号：2025-031 浙江海翔药业股份有限公司 关于股份回购进展情况的公告 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 浙江海翔药业股份有限公司 董 事 会 二、其他说明 公司后续将根据市场情况在回购期限内择机实施本次回购计划， ...

Group 1 - The company has approved a guarantee limit of up to RMB 200 million for its subsidiary, Hong Kong Gangxiang International Holdings Limited [1] - The company has recently renewed a guarantee agreement with HSBC Bank (China) Co., Ltd., providing a joint liability guarantee of USD 16.5 million for banking operations [2] - As of June 13, 2025, the total guarantee amount provided by the company to its subsidiaries is RMB 268.5492 million, with a remaining guarantee balance of RMB 106.8475 million [2]

证券代码：002099 证券简称：海翔药业 公告编号：2025-030 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江海翔药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 28 日召开了第七届董事会第十四次会议,2025 年 5 月 21 日召开了 2024 年年度股 东大会，审议通过了《关于为合并报表范围内子公司提供担保额度的议案》， 同意为合并报表范围内子公司港翔国际控股（香港）有限公司（以下简称"香 港港翔"）提供不超过人民币 20,000 万元（或等值外币）担保额度。具体详见 公司于 2025 年 4 月 29 日在《证券时报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）上披露的《关于为合并报表范围内子公司提供担保额度 的公告》（公告编号：2025-016）。 2023 年 2 月 3 日，公司与汇丰银行（中国）有限公司签署《保证书》，同 意为香港港翔开展各类银行业务提供 1,650 万元美金连带责任担保，并于 2023 ...

证券代码：002099 证券简称：海翔药业 公告编号：2025-029 截至 2025 年 5 月 31 日，公司尚未开始实施本次回购。 二、其他说明 公司后续将根据市场情况在回购期限内择机实施本次回购计划，并将在回购 期间根据相关法律法规等规定及时履行信息披露义务，敬请广大投资者注意投资 风险。 特此公告。 浙江海翔药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（w ...

浙江海翔药业股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 截至 2025 年 5 月 31 日，公司尚未开始实施本次回购。 证券代码：002099 证券简称：海翔药业 公告编号：2025-029 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 ...

Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]

Group 1 - The company's stock experienced abnormal trading fluctuations, with a cumulative price increase exceeding 20% over two consecutive trading days on May 22 and May 23, 2025 [1] - The company reported a decline in revenue for the year 2024, with total revenue of approximately 1.94 billion yuan, a year-on-year decrease of 10.75%, and a net loss attributable to shareholders of approximately 330.27 million yuan, an increase of 21.38% year-on-year [1] - For the first quarter of 2025, the company reported revenue of approximately 486.43 million yuan, a year-on-year decrease of 7.95%, and a net profit attributable to shareholders of approximately 9.23 million yuan, a decline of 71.68% year-on-year [1] Group 2 - The company approved a share repurchase plan, intending to use self-owned or raised funds to repurchase shares through centralized bidding, with a total repurchase amount not less than 150 million yuan and not exceeding 300 million yuan, at a price not exceeding 7.46 yuan per share [2] - The board confirmed that there are no undisclosed significant matters that should be disclosed according to the Shenzhen Stock Exchange regulations, and no prior information requires correction or supplementation [2]

证券代码：002099 证券简称：海翔药业 公告编号：2025-028 浙江海翔药业股份有限公司 关于股票交易异常波动的公告 3、公司控股股东、实际控制人不存在应披露而未披露的重大事项； 4、股票异动期间，公司控股股东、实际控制人不存在买卖公司股票的行 为； 5、公司于2025年4月9日召开第七届董事会第十三次会议，审议通过了《关 于回购股份方案的议案》，同意公司使用自有/自筹资金以集中竞价交易方式回 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 浙江海翔药业股份有限公司（以下简称"公司"）股票（证券简称：海翔 药业，证券代码：002099）于2025年5月22日、2025年5月23日连续2个交易日收 盘价格涨幅偏离值累计超过了20%，根据深圳证券交易所（以下简称"深交 所"）的有关规定，属于股票交易异常波动的情况。 二、关注、核实情况说明 针对公司股票交易异常波动，公司对有关事项进行了核查；并向公司控股 股东及实际控制人、公司董事、监事及高级管理人员进行核实，现将有关情况 说明如下： 1、截至目前公司前期披露的信息不存在需要 ...

Core Viewpoint - The innovative pharmaceutical concept stocks are experiencing significant growth, with notable companies reaching historical highs [1] Group 1: Stock Performance - Xinlitai and Kelun Pharmaceutical both achieved historical highs in stock prices [1] - Yangguang Nuohe is approaching a 20% daily limit increase [1] - Zhongsheng Pharmaceutical previously hit a daily limit increase [1] - Haichen Pharmaceutical, Beida Pharmaceutical, and Hongbo Pharmaceutical saw stock prices rise over 10% [1] - Shutaishen, Haixiang Pharmaceutical, Tigermed, and Huahai Pharmaceutical experienced stock price increases of over 5% [1]

Group 1: Company Overview - In 2024, the pharmaceutical industry faced intensified competition, leading to a 10.75% decline in product prices [2] - The company achieved a net profit attributable to shareholders of -3.30 billion yuan, a year-on-year increase of 21.38% [2] - In Q1 2025, the company reported revenue of 4.86 billion yuan and a net profit of 651.46 million yuan after excluding non-recurring gains [2] Group 2: Product and Market Strategy - The company is focusing on strengthening its core product base while increasing R&D for new products [2] - The company has diversified its raw material drug pipeline into multiple therapeutic areas, including anti-infectives and dermatology [3] - The company is expanding its CMO/CDMO projects, with several potential collaborations in the pipeline [3] Group 3: Dye Business Insights - The dye segment includes high-performance eco-friendly dyes, with the main product KN-R recognized as a "Manufacturing Industry Single Champion Product" [4] - The company is adopting an integrated business model from basic chemical raw materials to dye intermediates and dyes, enhancing resource allocation and production efficiency [4] - Due to market changes and rising raw material costs, the company has adjusted prices for some dye products [4]